Document is current
Any future updates will be listed below
-
Authors
,
Engel, Christoph
Rhiem, Kerstin
Hahnen, Eric
Loibl, Sibylle
Weber, Karsten E.
Seiler, Sabine
Zachariae, Silke
Hauke, Jan
Wappenschmidt, Barbara
Waha, Anke
Blümcke, Britta
Kiechle, Marion
Meindl, Alfons
Niederacher, Dieter
Bartram, Claus R.
Speiser, Dorothee
Schlegelberger, Brigitte
Arnold, Norbert
Wieacker, Peter
Leinert, Elena
Gehrig, Andrea
Briest, Susanne
Kast, Karin
Riess, Olaf
Emons, Günter
Weber, Bernhard H. F.
Engel, Jutta
Schmutzler, Rita K.
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (110837)
-
More Information
Article History
Received: 27 April 2017
Accepted: 23 January 2018
First Online: 7 March 2018
Ethics approval and consent to participate
: The multicentre GC-HBOC registry and the multicentre GBG GeparSixto trial have been approved by the responsible ethics committees. Written informed consent to be enrolled in the GC-HBOC registry or the GBG GeparSixto trial, respectively, was obtained from all individuals whose data was used for the present analysis.
: Not applicable.
: Eric Hahnen, Kerstin Rhiem, Brigitte Schlegelberger, Rita Schmutzler: Advisory Board Astra Zeneca. Sibylle Loibl is member of the editorial board (Associate Editor) of BMC Cancer. All other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
